Potassium channel

Global 8K Market Report 2023: Increasing Demand for High-end Displays in the Consumer Electronics Market Drives Growth

Retrieved on: 
Friday, April 21, 2023
National Association of Broadcasters, NAB, Science, Partnership, TCL, PD, LG Electronics, NHK, Health, Electronics, Telecommunications, COVID-19, Samsung, Samsung Galaxy S22, Information technology, Samsung Galaxy S23, Sale, Generation Z, ETRI, Ministry, NHK Science & Technology Research Laboratories, Sharp, Ministry of Industry and Information Technology, Personal computer, LG, Potassium channel, K, National Association, Leica, Japan Electronics and Information Technology Industries Association, JEITA, Television, Video game, Growth

Consumer electronics applications covered under the study include the usage of 8K in various technologies such as televisions, digital cameras, 8K monitors, PCs, and laptops, among others.

Key Points: 
  • Consumer electronics applications covered under the study include the usage of 8K in various technologies such as televisions, digital cameras, 8K monitors, PCs, and laptops, among others.
  • Due to the increasing demand for high resolution and image quality, 8K is widely used across consumer electronics.
  • The consumer electronics segment is continuously innovating technologies to offer their customers better-resolution products, creating a demand for 8K.
  • The increasing demand for smartphones among Gen Z and millennials with better camera quality further boosts the market demand.

GeneDx Rare Disease Data Demonstrates Utility in Drug Candidate Identification for Common Diseases

Retrieved on: 
Thursday, February 16, 2023
Sleep, Biology, De novo, Sleep apnea, Patient, Potassium channel, WGS, Depression, Clinical trial, Diabetes, Research, Author, Risk, Nature Genetics, GeneDx, Gene, Disease, TASK, KCNK3, Public, Drug discovery, Quality of life, Cardiovascular disease, Pharmaceutical industry

Such connections better enable the exploration of pharmacological solutions to common diseases impacting wide swaths of the general population.

Key Points: 
  • Such connections better enable the exploration of pharmacological solutions to common diseases impacting wide swaths of the general population.
  • Poor sleep quality often results in decreased quality of life and increased risk of comorbidities, such as cardiovascular disease, diabetes and depression.
  • TASK-1 is a K+ channel implicated in the control of breathing, but its link with sleep apnea remains poorly understood.
  • “Sleep apnea’s high prevalence and the imperfection of existing therapies mean there is sizeable appetite for developing new treatment approaches.”
    Through its robust rare disease data set, GeneDx is working to advance drug discovery and development, and accelerate research to help identify therapeutic targets for common diseases.

Foxtel evolves its partnership with CommScope launching the revolutionary new streaming iQ5 device

Retrieved on: 
Monday, November 22, 2021
TV and Radio, Data Management, Consumer Electronics, Technology, Entertainment, Telecommunications, Software, Networks, Audio, Video, Mobile, Wireless, Hardware, ABC iview, Foxtel Now, International, Amazon, Wi-Fi, Technology, Industry, Forward-looking statement, Product innovation, Telstra, Partnership, News, Australian Good Design Awards, Cardy, CommScope, Home, Paramount, Habit, Potassium channel, ABC, News Corporation, History, SBS (Australian TV channel), SBS, Element, Good, Season, Netflix, TB, COMM, Multimedia, Intelligence, NASDAQ, YouTube, IP, Cable television, Television, Video game console, Film, Risk management, CommScope, Foxtel, COMMSCOPE, FOXTEL

Thats why CommScope, a global leader in home networking solutions, was selected once again by Foxtel to provide their subscribers with the new iQ5 streaming set top box solution.

Key Points: 
  • Thats why CommScope, a global leader in home networking solutions, was selected once again by Foxtel to provide their subscribers with the new iQ5 streaming set top box solution.
  • Thats why CommScope , a global leader in home networking solutions, was selected once again by Foxtel to provide their subscribers with the new iQ5 streaming set top box solution .
  • CommScope worked closely together with Foxtel to bring the iQ5 to fruition, said Phil Cardy, Vice President, International PLM, Home Networks, CommScope.
  • The success of the iQ5 launch is a testament to the ability of both CommScope and Foxtel leveraging each others expertise.

 Evoca and CommScope Bring First-of-its-Kind Converged Broadcast-Broadband Network to Subscribers

Retrieved on: 
Wednesday, August 25, 2021
Technology, Mobile, Wireless, Entertainment, Telecommunications, Other Entertainment, Networks, TV and Radio, Hardware, Data Management, Industry, COMM, Aircraft pilot, Nextgen, ATSC 3.0, CommScope, Television, Potassium channel, ATSC, Internet, Product management, Android, Android TV, Name, Forward-looking statement, Multimedia, NASDAQ, Partnership, CEO, Achilles, Google, OTT, Technology, Cable television, Mobile phone, CommScope:, Evoca, COMMSCOPE:, EVOCA

Leveraging CommScopes expertise to develop the innovative VIP7802-ATSC set top solution is enabling Evoca to offer a unique television and entertainment content offering, said Ken Haase, Vice President, Product Management, CommScope.

Key Points: 
  • Leveraging CommScopes expertise to develop the innovative VIP7802-ATSC set top solution is enabling Evoca to offer a unique television and entertainment content offering, said Ken Haase, Vice President, Product Management, CommScope.
  • Evoca will provide their subscribers with a solution that will enhance their viewing experience and will also deliver aggregated streaming content.
  • Beginning Q1 2022, Pilot will be deployed to new subscribers on Evocas converged broadcast-broadband platform.
  • Evoca TVs Pilot provides a cost-effective way to roll out our unique Next Gen TV service to subscribers as we launch in multiple television markets, Achilles said.

Saniona to Host Research and Development (R&D) Day on Leveraging Ion Channel Targeting Expertise for Rare Diseases

Retrieved on: 
Wednesday, May 12, 2021
Branches of biology, Biology, Electrophysiology, Integral membrane proteins, Ion channels, Cell communication, Neurochemistry, Pharmacology, Potassium channel

Presenters will include members of Saniona\xe2\x80\x99s research team and executive management, as well as ion channel Key Opinion Leader (KOL) Heike Wulff, Ph.D., Professor of Pharmacology, University of California (UC) Davis School of Medicine.

Key Points: 
  • Presenters will include members of Saniona\xe2\x80\x99s research team and executive management, as well as ion channel Key Opinion Leader (KOL) Heike Wulff, Ph.D., Professor of Pharmacology, University of California (UC) Davis School of Medicine.
  • Dr. Wulff\xe2\x80\x99s research is focused on potassium channel pharmacology and the design of new ion channel modulating drugs and tool compounds.
  • Lead candidate SAN711 is entering Phase 1 for rare neuropathic disorders, with SAN903 for rare inflammatory and fibrotic disorders advancing through preclinical development.
  • Led by an experienced scientific and operational team, Saniona has an established research organization in Copenhagen, Denmark and is building its corporate office in the Boston, Massachusetts area, U.S.

Metrion Biosciences and LifeArc Further Extend Neuroscience-focused Ion Channel Drug Discovery Collaboration

Retrieved on: 
Monday, January 18, 2021
Biotechnology, Mental health, Medical devices, Health, Pharmaceutical, Branches of biology, Biology, Electrophysiology, Integral membrane proteins, Ion channels, Neurochemistry, Protein families, Potassium channel

Metrion Biosciences Limited (Metrion), the specialist ion channel CRO and drug discovery company, and LifeArc, a leading UK independent medical research charity, today announced a 12-month extension of their neuroscience drug discovery collaboration, as a result of the continued success of their ongoing agreement.

Key Points: 
  • Metrion Biosciences Limited (Metrion), the specialist ion channel CRO and drug discovery company, and LifeArc, a leading UK independent medical research charity, today announced a 12-month extension of their neuroscience drug discovery collaboration, as a result of the continued success of their ongoing agreement.
  • The collaboration is focused on the discovery of novel selective small molecular modulators of a specific two-pore domain potassium ion channel target, identified as likely to be involved in neurological pathogenesis, and has now progressed into the hit-to-lead optimisation phase.
  • Following the achievement of mutually agreed criteria LifeArc has now exercised the option to extend the programme for a further 12 months.
  • Under the terms of the agreement, Metrion provides validated ion channel and electrophysiology-based assays and safety profiling services.

Kv1.3 Potassium Channel Blockers - Pipeline Insight, 2019 - ResearchAndMarkets.com

Retrieved on: 
Friday, February 15, 2019
Health, Pharmaceutical, Branches of biology, Ion channels, Membrane proteins, Neurotoxins, Proteins, Channel blocker, Potassium channel, KCNA3

The "Kv1.3 Potassium Channel Blockers - Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Kv1.3 Potassium Channel Blockers - Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • Kv1.3 Potassium Channel Blockers - Pipeline Insight, 2019 offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Kv1.3 Potassium Channel Blockers development.
  • The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.
  • Offers detailed therapeutic product profiles of Kv1.3 Potassium Channel Blockers with key coverage of developmental activities including licensing & collaboration deals, patent details, designations, technologies, indications and chemical information
    Therapeutic assessment of the active pipeline products by stage, product type, molecule type, and route of administration
    Identify the product attributes and use it for target finding, drug repurposing, and precision medicine